Expression of T-cell activation marker CD134 (OX40) in lymphomatoid papulosis.

BACKGROUND: CD134/OX40 and CD30 are transmembrane proteins from the tumour necrosis factor receptor (TNFR) family present selectively on activated T cells. TNFR-related proteins are crucially involved in the regulation of proliferation and survival of normal and malignant lymphohaematopoietic cells. CD30 has been used for the immunophenotyping and subclassification of cutaneous lymphomas; virtually nothing is known, however, about the expression pattern of CD134 in lymphoid skin malignancies.

OBJECTIVES: To determine CD134 expression in cutaneous lymphoma and benign inflammatory disorders.

METHODS: Biopsy material was obtained from patients with lymphomatoid papulosis (LyP, n = 42), mycosis fungoides (n = 21), Jessner's infiltrates (n = 10) and non-specific dermatitis (n = 14). The expression of CD134 and CD30 was scored after immunohistochemical staining with appropriate monoclonal antibodies. The proportion of G2 + S phase cells was determined by laser scanning cytometry from nuclei obtained from paraffin-embedded biopsies.

RESULTS: Few, single and scattered CD134+ cells (< 10%) were observed in the benign inflammatory infiltrations and in mycosis fungoides. A subset of 16 patients with LyP presented with clusters of CD30+ CD134+ cells. There was no correlation between the magnitude of CD134 expression and the histological type or the proportion of G2 + S cells in LyP. CD134 immunoreactivity was lower than expected in patients with LyP and another lymphoid malignancy (P < 0.001, Fisher's exact test).

CONCLUSIONS: CD134 is strongly expressed in a proportion (38%) of patients with LyP, but not in mycosis fungoides or benign lymphocytic infiltrations. Loss of CD134 expression in LyP may be a marker of an increased risk of second lymphoid malignancy.